CN114259534A - Application of traditional Chinese medicine composition in preparation of medicine for treating low immune function and immune dysfunction - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating low immune function and immune dysfunction Download PDFInfo
- Publication number
- CN114259534A CN114259534A CN202210106790.6A CN202210106790A CN114259534A CN 114259534 A CN114259534 A CN 114259534A CN 202210106790 A CN202210106790 A CN 202210106790A CN 114259534 A CN114259534 A CN 114259534A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000036737 immune function Effects 0.000 title claims abstract description 17
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 4
- 241000737253 Lygodium japonicum Species 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 10
- 239000009910 sargent gloryvine Substances 0.000 claims abstract description 10
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 9
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 9
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 8
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 8
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 8
- 241000405414 Rehmannia Species 0.000 claims abstract description 8
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 6
- 235000006533 astragalus Nutrition 0.000 claims abstract description 6
- 240000006766 Cornus mas Species 0.000 claims abstract 4
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract 4
- 241000245665 Taraxacum Species 0.000 claims description 9
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 6
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 6
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 241000700159 Rattus Species 0.000 abstract description 24
- 238000002474 experimental method Methods 0.000 abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 22
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 18
- 239000008055 phosphate buffer solution Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000027939 micturition Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 241000209020 Cornus Species 0.000 description 6
- 241000207925 Leonurus Species 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 208000019206 urinary tract infection Diseases 0.000 description 4
- 230000003202 urodynamic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000292546 Taraxacum mongolicum Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241001257583 Microphyllum Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010046461 Urethral pain Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparing a medicine for treating low immune function and immune dysfunction, wherein the traditional Chinese medicine composition comprises the following components in parts by mass: 15-30 parts of lygodium japonicum stem, 40-50 parts of sargentgloryvine stem, 40-60 parts of dandelion, 10-30 parts of moutan bark, 10-20 parts of polygonum cuspidatum, 5-15 parts of dogwood, 10-30 parts of Chinese yam, 10-30 parts of poria cocos, 10-18 parts of rhizoma alismatis, 10-15 parts of motherwort herb, 10-25 parts of astragalus membranaceus and 10-15 parts of rehmannia. Experiments prove that the traditional Chinese medicine composition provided by the invention can effectively regulate the immune function of rats and can effectively treat low immune function and immune dysfunction.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparing a medicine for treating low immune function and immune dysfunction.
Background
Stranguria is a common disease of genitourinary system, and the main symptoms are urethral pain, frequent and urgent urination, unsmooth discharge and the like. Stranguria was first described in Huangdi's classic, and detailed in jin Kui Yao L ü e, which is described as "frequent and urgent urination in the form of millet, spasm of the lower abdomen, pain in the umbilicus", indicating the main manifestations of stranguria, frequent and urgent urination, poor discharge, spasm of the lower abdomen, pain in the waist and abdomen. In the treatise on the etiology and pathogenesis, it is indicated that the stranguria is caused by kidney deficiency and bladder heat, and that the location of stranguria is kidney and bladder. The symptoms of the disease are similar to the urinary tract infection in modern medicine, the urinary tract infection becomes the second largest infectious disease clinically after respiratory tract infection, the disease incidence rate is 2.0-5.0% abroad, the disease incidence rate is about 0.91% in China, the urinary tract infection incidence rate is on the rising trend with the increase of age, especially, the disease incidence rate of women is far higher than that of men (8:1-10:1), wherein the disease incidence rate of middle-aged and young women is about 2.05%, the disease incidence rate of 65-70 years old women is about 15-20%, and the disease incidence rate of women over 80 years old is about 20-50%.
Studies show that stranguria is often accompanied by the change of human immune function, and the persistence of stranguria can cause CD3 in human body+、CD4+And CD4+/CD8+The content of the components is obviously changed, so that the immunologic hypofunction and the immunologic dysfunction of the human body are caused.
Disclosure of Invention
The invention aims to provide the application of the traditional Chinese medicine composition in preparing the medicines for treating the low immune function and the immune dysfunction, and the traditional Chinese medicine composition can effectively improve the urination function and the abnormal change of T lymphocyte subsets caused by stranguria, thereby indicating that the traditional Chinese medicine composition can effectively treat the low immune function and the immune dysfunction of human bodies.
The first object of the present invention is achieved by the following means. The application of the traditional Chinese medicine composition in preparing the medicine for treating low immune function and immune dysfunction comprises the following components in parts by mass: 15-30 parts of lygodium japonicum stem, 40-50 parts of sargentgloryvine stem, 40-60 parts of dandelion, 10-30 parts of moutan bark, 10-20 parts of polygonum cuspidatum, 5-15 parts of dogwood, 10-30 parts of Chinese yam, 10-30 parts of poria cocos, 10-18 parts of rhizoma alismatis, 10-15 parts of motherwort, 10-25 parts of astragalus membranaceus, 10-15 parts of rehmannia glutinosa
The second purpose of the invention is to provide application of a traditional Chinese medicine composition in preparing a medicine for treating low immune function and immune dysfunction caused by stranguria, wherein the traditional Chinese medicine composition comprises the following components in parts by mass: 15-30 parts of lygodium japonicum stem, 40-50 parts of sargentgloryvine stem, 40-60 parts of dandelion, 10-30 parts of moutan bark, 10-20 parts of polygonum cuspidatum, 5-15 parts of dogwood, 10-30 parts of Chinese yam, 10-30 parts of poria cocos, 10-18 parts of rhizoma alismatis, 10-15 parts of motherwort herb, 10-25 parts of astragalus membranaceus and 10-15 parts of rehmannia.
Further preferably, the traditional Chinese medicine composition comprises the following components in parts by mass: 20 parts of lygodium japonicum stem, 50 parts of sargentgloryvine stem, 40 parts of dandelion, 10 parts of moutan bark, 10 parts of giant knotweed rhizome, 10 parts of rehmannia root, 10 parts of dogwood, 10 parts of Chinese yam, 10 parts of poria cocos, 10 parts of rhizoma alismatis, 10 parts of motherwort and 10 parts of astragalus root.
The lygodium japonicum has pharmacological effects of bacteriostasis, anti-inflammation, analgesia and the like, and has obvious curative effect on treating urinary system diseases such as urinary tract infection, kidney stone and the like; the sargentgloryvine stem has wide clinical application, can be used for treating rheumatic arthralgia and heat-toxin pyocutaneous disease, and has the effects of resisting bacteria, viruses, inflammation, immunosuppression and the like; the dandelion has broad-spectrum antibacterial effect, and can be clinically used for treating diseases such as urinary heat stranguria due to the compatibility of other traditional Chinese medicines; paeonol as main ingredient of cortex moutan has antibacterial, analgesic, antiinflammatory, and immunity enhancing effectsAnd the like; the related pharmacological research of the giant knotweed rhizome shows that the giant knotweed rhizome has the functions of resisting infection, resisting inflammation and the like, and is mainly used for treating diseases such as rheumatic arthralgia, carbuncle, swelling, sore and the like clinically. Model rat CD3 treated by the traditional Chinese medicine composition+、CD4+、CD4+Significantly elevated/CD 8, CD8+The traditional Chinese medicine composition provided by the invention can effectively regulate the immune function of rats and can effectively treat the hypoimmunity and the immunologic dysfunction of human bodies.
Detailed Description
The following embodiments are given as examples of the present invention, and are not intended to limit the present invention in any way, and it will be understood by those skilled in the art that the present invention may be embodied in many forms without departing from the spirit and scope of the present invention.
The lygodium japonicum stem used in the invention is a dried aerial part of lygodium japonicum (Thunb.) SW., lygodium japonicum microphyllum (Cav.) R.Br. or lygodium japonicum (L.) SW..
The sargentgloryvine stem used in the invention is a dried rattan of sargentodoxacacea (Oliv.) Rehd. et wils.
The dandelion used in the invention is the dried whole herb of Taraxacum mongolicum hand-processed, Taraxacum mongolicum Kitam, or several plants of the same genus.
The tree peony bark used in the invention is the dried root bark of Paeoniaffrutinosa Andr.
The giant knotweed used in the invention is dried rhizome and root of Polygonum cuspidatum Polygonum Sieb.
The rehmanniae radix used in the invention is fresh or dry root tuber of rehmannia Rehmanniaglutinosalibisch.
The dogwood used in the invention is dry mature pulp of cornus officinalis of the family dogwood Cornusoficinalisis Sieb.
The yam used in the invention is dried rhizome of Dioscorea opposita oppositatthunb.
The Poria cocos used in the invention is dried sclerotium of Poriacos (Schw.) Wolf, a fungus of Polyporaceae.
The Alisma orientale used in the invention is a dried tuber of Alisma orientalis (Sam.) Juzep.
The herba leonuri used by the invention is fresh or dry aerial parts of leonurus japonica houtt.
The astragalus root used in the invention is the dried root of astragalus mongholicus astragalusmebranaceus (Fisch.) of leguminosae or astragalusmebranaceus (Fisch.) Hsiao.
Experimental Material
Laboratory animal
60 6-week-old female SD (350 + -10 g) rats, purchased from Guangzhou university of traditional Chinese medicine animal center, animal quality certification number: 44005800007539. the feed is bred in the experimental animal center of Guangzhou Chinese medicinal university, and the license number is as follows: SCXK (Yue) 2013-. The breeding room conditions are as follows: the humidity is 60 + -5%, the temperature is 25 + -2 deg.C, the day and night time is 12h, and the animal feed is given at regular time every day and the drinking water and padding are replaced.
Instrument equipment
Urine dynamic instrument (LABORIE MEDICAL TECHNOLOGIES, model: UDS-94-BT)
Catheter, micro-syringe pump (Zhejiang Smith medical instruments, Inc., model WZ-50C6), flow cytometer (BD, model: FACS Canto 2), test tube, pipette, centrifuge, bacteria incubator (Beijing Wuzhou science and technology development, Inc., model: CO-150), McLeibodle turbidimeter (Zhuhai Besso Biotechnology, Inc., model BS-MFL-01), catheter, cell counter.
Primary drugs and agents
A Chinese medicinal composition; the composition comprises the following components in parts by mass: 20 parts of lygodium japonicum stem, 50 parts of sargentgloryvine stem, 40 parts of dandelion, 10 parts of moutan bark, 10 parts of giant knotweed rhizome, 10 parts of rehmannia root, 10 parts of dogwood, 10 parts of Chinese yam, 10 parts of poria cocos, 10 parts of rhizoma alismatis, 10 parts of motherwort and 10 parts of astragalus root.
The preparation method of the traditional Chinese medicine composition comprises the following steps:
(1) grinding the traditional Chinese medicine components into powder, and sieving the powder by a 100-mesh sieve.
(2) Mixing the traditional Chinese medicine components in the step (1), and adding water with the weight 10 times of the total weight of the components to soak for 40 min; .
(3) And (3) steaming and boiling the components in the step (2) and soaking water at the temperature of 100 ℃ until the mass ratio of the water to the traditional Chinese medicine components is 1: 2.
(4) Adding water 10 times the total mass of the components into the mixture obtained in the step (3), steaming at 100 deg.C until the mass ratio of water to Chinese medicinal components is 1:0.2, filtering with 100 mesh filter paper, and collecting fluid extract; continuously steaming the concentrated extract until the density is less than or equal to 1.20g/cm3Drying and tabletting.
(5) Coating the tablets obtained in the step (4).
Three-gold tablet: guilin Sanjin pharmaceutical industry Co., Ltd, batch number: 171227, respectively;
escherichia coli O111B4Standard strains: provided by the microbiological research laboratory of the basic medical institute of Guangzhou Chinese medicine university;
a chloral hydrate solution; erythrocyte lysate: tiangen Biochemical technology, batch number: RT 122-02;
LB broth culture medium: cool ber SCIENCE, batch number: PM 0010-500G;
agar; biosharp, lot number: B0013K 010500.
Experimental methods
Bacterial liquid culture
O for experiment111B4Escherichia coli solution, inoculated in meat soup culture medium (15g agar +25g LB broth medium/1000 ml), 37 degrees culture box broth culture for 18 hours, with PBS (phosphate buffer solution) diluted bacterial liquid, 7.5 x 108/ml (McLee's value for 2.5) bacterial suspension for use.
Animal modeling and grouping
After 3d acclimation, 60 SD female rats were divided into normal group (n-10) and artificial group (n-50) according to random number sequence. Rats were deprived of water for 18h and then anesthetized with 10% chloral hydrate, in the supine position, with the hind legs fixed separately. The tissue clip is used to clamp one side of the nipple of the urethra and slightly lift it off the abdomen. The catheter is inserted into the urethra for about 2cm, urine is extracted, 0.5ml of the prepared escherichia coli solution is slowly injected into the bladder to establish a stranguria model [10], and 0.5ml of PBS is injected into normal rats. Water was prohibited within 1h after inoculation. After inoculation of bacteria, rats in the model group are randomly divided into a model group, a positive group (2.625 g/d.kg of three-gold tablets), a high (5.43 g/d.kg) dose group, a medium (2.71 g/d.kg) dose group and a low (1.36 g/d.kg) dose group of the traditional Chinese medicine composition, and 10 rats in each group. The rats in each group were administered with gastric lavage for 3 consecutive days according to the corresponding dose, and the rats in the normal group model group were administered with distilled water at equal doses by gastric lavage, during which time the rats in each group were free to eat and drink water.
Bladder function assay
After 3 days of continuous gavage, turbidity removal and detoxification, rats were anesthetized with 10% chloral hydrate and fixed. The catheter was inserted into the bladder from the urethra and connected to a urodynamic instrument and a micro-syringe pump through a 3F tube at a pump speed of 9 ml/h. Before pressure measurement, The Bladder of The rat is emptied, The Bladder pressure at which The urine overflows spontaneously is recorded, i.e. The Bladder Leak Point Pressure (BLPP), at which Point The perfusion is stopped, and The pressure curve and The number of non-voiding contractions before voiding (The frequency of non-voiding contacts, NVCs) are observed. The peak value of the Pressure curve is the Maximum Bladder Pressure (MVP), the perfusion time × the perfusion rate, i.e., the Maximum Bladder Capacity (MBC), is calculated, the Residual liquid in the Bladder is extracted through the perfusion tube by a syringe, the Volume is the Residual urine Volume (PVR), the Compliance BC (BC ═ Δ V/Δ P), the urine discharge VV (voidvolume VV, VV ═ MBC-PVR) is calculated, and the urine discharge rate EV (EV ═ V/MBC × 100%). The above operations are repeated for 2-3 times, and the average value is taken and counted.
T lymphocyte subpopulation analysis
After the urodynamic test, peripheral blood T lymphocyte subpopulation analysis was performed 2h after administration to each group of rats the following morning, as follows:
firstly, collecting 5mL of anticoagulation blood from abdominal aorta, centrifuging for 5min at 450g, removing supernatant, and taking about 2mL of precipitate.
② adding erythrocyte lysate (about 6ml) according to the instruction, shaking up and down, standing, and cracking for 5 min. Then, the mixture was centrifuged at 450g for 5min to remove the liquid.
③ after 3 times of cracking, carefully removing the supernatant, washing, then centrifuging for 5min at 450g, and discarding the supernatant. Finally, the cells were resuspended in 1ml PBS.
Fourthly, counting by a cell counting plate, and adjusting the cell concentration to be 1 multiplied by 107And/ml, blowing, beating and mixing uniformly.
Fifthly, taking 250ul of the resuspension liquid in a marked flow tube, and adding PBS to make up to 1200 ul. Wherein the conditions of each sample tube are respectively as follows: the No. 1 sample tube is CD3+(singly stain, take 0.5ul of CD3 antibody, add 50ul of PBS), No. 2 sample tube is CD4+(singly stain, take 0.5ul of CD4 antibody, add 50ul of PBS), No. 3 sample tube is CD8+(singly stain, take CD8 antibody 0.5ul, add PBS 50ul), No. 4 sample tube is the three-stain tube (each antibody 0.5ul, add PBS 50 ul).
Sixthly, incubating for 30min in a refrigerator at 4 ℃ in the dark.
Seventhly, taking out the flow tube, centrifuging for 5min at the temperature of 4 ℃ in a dark place by 450g, removing supernatant, and adding 1ml of PBS for resuspension.
Adding 1ml of PBS, centrifuging, removing the supernatant, adding 1ml of PBS into the precipitate for resuspension, and detecting by a sample flow cytometer.
Statistical method
The data analysis processing is carried out by using SPSS17.0 statistical software, and the data are averaged plus or minus standard deviation
As shown, comparisons between groups were analyzed by one-way anova, with P <0.05 indicating statistical significance.
Results of the experiment
The urodynamic constant results are shown in table 1:
TABLE 1
Note: in comparison with the normal group,*P<0.05,**P<0.01；in comparison to the set of models,#P<0.05,##P<0.01。
as can be seen from table 1, compared to the normal group, the model group rats had significantly decreased MBC, EV, BC (P <0.01), and significantly increased BLPP, MVP, NVCs (P < 0.01); compared with the model group, the MBC and BC of the rats in the positive group are remarkably increased (P <0.01 or P <0.05), and the BLPP, MVP and NVCs are remarkably reduced (P < 0.01); compared with a model group, the BLPP, MVP and NVCs of the traditional Chinese medicine composition in the high-dose group and the low-dose group are obviously reduced (P is less than 0.01), the MBC and the EV are increased, wherein the BC of the traditional Chinese medicine composition in the high-dose group is enhanced, and the BC of the turbidity-clearing pill-removing low-dose group is obviously enhanced (P is less than 0.01); the dosage groups BLPP, MVP and NVCs in the traditional Chinese medicine composition are obviously reduced (P is less than 0.05),
the results of peripheral blood T lymphocyte subpopulations are shown in table 2:
TABLE 2
| Group of | CD3+ | CD4+ | CD8+ | CD4+/CD8+ |
| Is normal | 0.56±0.12 | 0.40±0.11 | 0.16±0.11 | 2.50±0.46 |
| Model (model) | 0.50±0.23* | 0.30±0.12** | 0.19±0.11* | 1.58±0.45** |
| Positive for | 0.55±0.14# | 0.39±0.23## | 0.17±0.11 | 2.32±0.47## |
| Height of | 0.56±0.27# | 0.39±0.25## | 0.17±0.12 | 2.24±0.56## |
| In | 0.56±0.22# | 0.41±0.22## | 0.16±0.08## | 2.59±0.67## |
| Is low in | 0.53±0.13# | 0.38±0.12# | 0.15±0.07## | 2.60±0.52## |
Note: in comparison with the normal group,*P<0.05，**P<0.01; and model groupIn contrast to the above-mentioned results,#P<0.05，##P<0.01。
as can be seen from Table 2, the model group CD3 was compared with the normal group+、CD4+、CD4+/CD8+Significantly reduce (P)<0.01 or P<0.05)，CD8+Is remarkably increased (P)<0.05); positive group CD3 compared to model group+、CD4+、CD4+/CD8+Is remarkably increased (P)<0.01 or P<0.05); compared with the model group, the Chinese medicinal composition has high dose group CD3+、CD4+、CD4+/CD8+Is remarkably increased (P)<0.01 or P<0.05)，CD8+Decrease (P)<0.05); medium-dosage group of Chinese medicinal composition CD3+、CD4+、CD4+/CD8+Is remarkably increased (P)<0.01 or P<0.05)，CD8+Significantly reduce (P)<0.01); low-dose group of Chinese medicinal composition CD3+、CD4+、CD4+/CD8+Is remarkably increased (P)<0.01 or P<0.05)，CD8+Significantly reduce (P)<0.01)。
And (4) conclusion:
urodynamics examination is a very effective method for clinically diagnosing lower urinary tract dysfunction, MBC, EV and BC of a stranguria rat treated by the traditional Chinese medicine composition are increased, BLPP, MVP and NVCs are reduced, and indexes are close to those of a normal group in different degrees, so that the traditional Chinese medicine composition has the curative effects of improving the frequent micturition, urgent micturition, incomplete urine and the like of the stranguria rat, and can effectively improve the urination and urine storage functions of the stranguria rat.
In recent years, studies have shown that stranguria is often accompanied by changes in immune function. The research result of the experiment shows that the stranguria model rat CD3+、CD4+And CD4+/CD8+All are significantly reduced, CD8+Obviously increases, which indicates that the organism immunity of the stranguria rats is reduced and the immune function is disordered. Model rat CD3 treated by traditional Chinese medicine composition+、CD4+、CD4+Significantly elevated/CD 8, CD8+Obviously reduced to normal level, which shows that the traditional Chinese medicine composition can regulate the immune function of the stranguria rats.
Claims (3)
1. The application of the traditional Chinese medicine composition in preparing the medicine for treating low immune function and immune dysfunction is characterized in that the traditional Chinese medicine composition comprises the following components in parts by mass: 15-30 parts of lygodium japonicum stem, 40-50 parts of sargentgloryvine stem, 40-60 parts of dandelion, 10-30 parts of moutan bark, 10-20 parts of polygonum cuspidatum, 5-15 parts of dogwood, 10-30 parts of Chinese yam, 10-30 parts of poria cocos, 10-18 parts of rhizoma alismatis, 10-15 parts of motherwort herb, 10-25 parts of astragalus membranaceus and 10-15 parts of rehmannia.
2. The application of the traditional Chinese medicine composition in preparing the medicine for treating the low immune function and the immune dysfunction caused by stranguria is characterized in that the traditional Chinese medicine composition comprises the following components in parts by mass: 15-30 parts of lygodium japonicum stem, 40-50 parts of sargentgloryvine stem, 40-60 parts of dandelion, 10-30 parts of moutan bark, 10-20 parts of polygonum cuspidatum, 5-15 parts of dogwood, 10-30 parts of Chinese yam, 10-30 parts of poria cocos, 10-18 parts of rhizoma alismatis, 10-15 parts of motherwort herb, 10-25 parts of astragalus membranaceus and 10-15 parts of rehmannia.
3. The use of the traditional Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for treating immune hypofunction and immune dysfunction caused by stranguria, wherein the traditional Chinese medicine composition comprises the following components in parts by mass: 20 parts of lygodium japonicum stem, 50 parts of sargentgloryvine stem, 40 parts of dandelion, 10 parts of moutan bark, 10 parts of giant knotweed rhizome, 10 parts of rehmannia root, 10 parts of dogwood, 10 parts of Chinese yam, 10 parts of poria cocos, 10 parts of rhizoma alismatis, 10 parts of motherwort and 10 parts of astragalus root.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110168542.XA CN112807369A (en) | 2021-02-07 | 2021-02-07 | Traditional Chinese medicine composition for treating stranguria and preparation method thereof |
| CN202110168542X | 2021-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114259534A true CN114259534A (en) | 2022-04-01 |
Family
ID=75862166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110168542.XA Pending CN112807369A (en) | 2021-02-07 | 2021-02-07 | Traditional Chinese medicine composition for treating stranguria and preparation method thereof |
| CN202210106790.6A Pending CN114259534A (en) | 2021-02-07 | 2022-01-28 | Application of traditional Chinese medicine composition in preparation of medicine for treating low immune function and immune dysfunction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110168542.XA Pending CN112807369A (en) | 2021-02-07 | 2021-02-07 | Traditional Chinese medicine composition for treating stranguria and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112807369A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555867A (en) * | 2004-01-08 | 2004-12-22 | 韦品清 | Chinese herbal medicinal compositon for treating prostate disease |
| CN110812429A (en) * | 2019-12-18 | 2020-02-21 | 卓和药业集团有限公司 | Pharmaceutical composition and syrup |
-
2021
- 2021-02-07 CN CN202110168542.XA patent/CN112807369A/en active Pending
-
2022
- 2022-01-28 CN CN202210106790.6A patent/CN114259534A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555867A (en) * | 2004-01-08 | 2004-12-22 | 韦品清 | Chinese herbal medicinal compositon for treating prostate disease |
| CN110812429A (en) * | 2019-12-18 | 2020-02-21 | 卓和药业集团有限公司 | Pharmaceutical composition and syrup |
Non-Patent Citations (2)
| Title |
|---|
| 史振铎: "清浊祛毒丸治疗下尿路症状专家共识", 《中国男科学杂志》 * |
| 胡献国等: "《补药之长-黄芪》", 31 August 2014, 人民军医出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112807369A (en) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100346819C (en) | Chinese medicinal preparation for treating prostate disease and its production method | |
| WO2022057360A1 (en) | Pharmaceutical composition for use preventing and curing respiratory diseases in winter | |
| CN106924477B (en) | Composite traditional Chinese medicine fermentation preparation produced by mixed bacteria fermentation and preparation method thereof | |
| CN103583898B (en) | Chinese medicinal herb-containing feed additive capable of preventing weaned pig multisystem failure syndrome and pig feed containing same | |
| CN107184702B (en) | Traditional Chinese medicine composition for preventing and treating proventriculitis and myogastritis of poultry and preparation method thereof | |
| CN104288217A (en) | Traditional Chinese medicine composition and application thereof | |
| CN101007026A (en) | An anticancer medicinal composition, preparing method and use thereof | |
| CN114903944B (en) | Composition and preparation for improving cervical HPV infection symptoms and preparation method | |
| CN114259534A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating low immune function and immune dysfunction | |
| CN115105502B (en) | Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine | |
| CN102813713B (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
| CN104758517A (en) | A medicine composition for treating xenorhabdus infection of livestock and poultry | |
| CN109568430B (en) | Preparation method and application of immunopotentiator | |
| CN1899499A (en) | Chinese medicine composition for treating cold and its preparing method and use | |
| CN113876862B (en) | Malassezia-resistant traditional Chinese medicine composition and application thereof | |
| CN117379505B (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
| CN115715783B (en) | Traditional Chinese medicine composition for preventing and treating white diarrhea of pigs and preparation method thereof | |
| CN108853195B (en) | Pharmaceutical composition for treating porcine epidemic diarrhea | |
| CN117257866B (en) | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof | |
| CN115919951B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN111249421B (en) | Traditional Chinese medicine preparation for treating initial damp-heat exogenous fever as well as preparation method and application thereof | |
| CN102813726B (en) | Compound traditional Chinese medicine submicron powder preparation for preventing and treating humid-heat diarrhea of poultry and preparation method thereof | |
| CN115006488B (en) | Pharmaceutical composition for preventing and treating proventriculitis and myogastritis of poultry and preparation method and application thereof | |
| CN109432272B (en) | Traditional Chinese medicine composition and medicine for treating non-gonococcal urethritis and preparation method thereof | |
| CN1698755A (en) | Method for preparing Chinese medicinal tablet for treating prostate disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |